Renal Insufficiency, Chronic
"Renal Insufficiency, Chronic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)
Descriptor ID |
D051436
|
MeSH Number(s) |
C12.777.419.780.750 C13.351.968.419.780.750
|
Concept/Terms |
Renal Insufficiency, Chronic- Renal Insufficiency, Chronic
- Chronic Renal Insufficiencies
- Renal Insufficiencies, Chronic
- Chronic Renal Insufficiency
- Kidney Insufficiency, Chronic
- Chronic Kidney Insufficiency
- Chronic Kidney Insufficiencies
- Kidney Insufficiencies, Chronic
Chronic Kidney Diseases- Chronic Kidney Diseases
- Chronic Kidney Disease
- Disease, Chronic Kidney
- Diseases, Chronic Kidney
- Kidney Disease, Chronic
- Kidney Diseases, Chronic
- Chronic Renal Diseases
- Chronic Renal Disease
- Disease, Chronic Renal
- Diseases, Chronic Renal
- Renal Disease, Chronic
- Renal Diseases, Chronic
|
Below are MeSH descriptors whose meaning is more general than "Renal Insufficiency, Chronic".
Below are MeSH descriptors whose meaning is more specific than "Renal Insufficiency, Chronic".
This graph shows the total number of publications written about "Renal Insufficiency, Chronic" by people in this website by year, and whether "Renal Insufficiency, Chronic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2008 | 1 | 0 | 1 |
2010 | 4 | 1 | 5 |
2011 | 4 | 0 | 4 |
2012 | 6 | 3 | 9 |
2013 | 8 | 3 | 11 |
2014 | 9 | 3 | 12 |
2015 | 16 | 2 | 18 |
2016 | 8 | 0 | 8 |
2017 | 11 | 4 | 15 |
2018 | 12 | 3 | 15 |
2019 | 14 | 1 | 15 |
2020 | 12 | 3 | 15 |
2021 | 11 | 3 | 14 |
2022 | 17 | 1 | 18 |
2023 | 12 | 2 | 14 |
2024 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Renal Insufficiency, Chronic" by people in Profiles.
-
Modeling Metformin and Dapagliflozin Pharmacokinetics in Chronic Kidney Disease. AAPS J. 2024 Aug 19; 26(5):94.
-
Frailty, but not cognitive impairment, improves mortality risk prediction among those with chronic kidney disease-a nationally representative study. BMC Nephrol. 2024 May 22; 25(1):177.
-
Real-World Impact of Blood Pressure Control in Patients With Apparent Treatment-Resistant or Difficult-to-Control Hypertension and Stages 3 and 4 Chronic Kidney Disease. Am J Hypertens. 2024 05 15; 37(6):438-446.
-
Disturbed flow in the juxta-anastomotic area of an arteriovenous fistula correlates with endothelial loss, acute thrombus formation, and neointimal hyperplasia. Am J Physiol Heart Circ Physiol. 2024 06 01; 326(6):H1446-H1461.
-
Associations of Kidney Functional Magnetic Resonance Imaging Biomarkers with Markers of Inflammation in Individuals with CKD. Kidney360. 2024 May 01; 5(5):681-689.
-
Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials. BMJ Open. 2024 Mar 19; 14(3):e076444.
-
Rilparencel (Renal Autologous Cell Therapy-REACT®) for Chronic Kidney Disease and Type 1 and Type 2 Diabetes: Phase 2 Trial Design Evaluating Bilateral Kidney Dosing and Redosing Triggers. Am J Nephrol. 2024; 55(3):389-398.
-
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis. Ann Intern Med. 2023 12; 176(12):1606-1616.
-
Oral Sodium Bicarbonate and Bone Turnover in CKD: A Secondary Analysis of the BASE Pilot Trial. J Am Soc Nephrol. 2024 01 01; 35(1):57-65.
-
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation. 2024 02 06; 149(6):450-462.